Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
-$5.5M |
 |
Gilead SciencesGILD |
-$4.04B |
 |
AmgenAMGN |
-$189M |
 |
Editas MedicineEDIT |
-$7M |
 |
Crispr TherapeuticsCRSP |
-$163M |
Are Lexaria Bioscience Insiders Buying or Selling?
Lexaria Bioscience (LEXX) has had no reported insider transactions in the past 90 days. The most recent was CHRISTOPHER BUNKA, who bought 11,900 shares at $0.91 on July 30, 2025.
Insider trading patterns can signal confidence or concern from the people who know the company best. AltIndex tracks insider transactions as one of 25+ alternative data signals in the LEXX AI Score. For government officials trading this stock, see LEXX congressional trading.
Who’s Trading Lexaria Bioscience Stock?
| Insider | Activity | Trades | Last Trade |
|---|---|---|---|
| RICHARD CHRISTOPHER | Bought $130,000 | 3 | Jul 29, 2025 |
| CHRISTOPHER BUNKA | Bought $25,000 | 2 | Jul 30, 2025 |
| DOCHERTY JOHN MARTIN | Bought $5,000 | 1 | Jul 29, 2025 |
| McKechnie William Edward | Bought $4,500 | 1 | Jul 29, 2025 |
| Vanessa Carle | Bought $680 | 1 | Jul 29, 2025 |
Recent Lexaria Bioscience Insider Transactions
| Insider | Transaction Date | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| CHRISTOPHER BUNKA | Jul 30, 2025 | Buy | 11,900 | $0.91 | $11,000 |
| CHRISTOPHER BUNKA | Jul 29, 2025 | Buy | 15,600 | $0.92 | $14,000 |
| RICHARD CHRISTOPHER | Jul 29, 2025 | Buy | 15,000 | $0.91 | $14,000 |
| McKechnie William Edward | Jul 29, 2025 | Buy | 5,000 | $0.91 | $4,500 |
| DOCHERTY JOHN MARTIN | Jul 29, 2025 | Buy | 5,376 | $0.93 | $5,000 |
| Vanessa Carle | Jul 29, 2025 | Buy | 750 | $0.91 | $680 |
| RICHARD CHRISTOPHER | Dec 3, 2024 | Buy | 27,172 | $2.47 | $67,000 |
| RICHARD CHRISTOPHER | Dec 2, 2024 | Buy | 22,828 | $2.24 | $51,000 |
Frequently Asked Questions: Lexaria Bioscience Insider Trading
Lexaria Bioscience insiders have not reported any transactions in the past 90 days.
Insider buying is generally a stronger signal than insider selling, since insiders may sell for personal reasons (diversification, taxes) but typically buy only when they believe the stock is undervalued. AltIndex uses insider transaction patterns alongside 25+ other signals in the AI Score.
CHRISTOPHER RICHARD has bought the most LEXX stock in the last 2 years, with a total value of $130,000.
According to our estimates, the total value of insider transactions for Lexaria Bioscience in the last 2 years is positive, amounting to $170,000. This indicates that insiders have predominantly bought shares, showcasing their confidence in the company's future prospects.
